PharmaBoardroom

Interview with Ian Chalmers, Chief Executive, Medicines Australia

To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the national industry…

Interview with Jean-Pierre Salama, CEO, Pharmacor

Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical…

Interview with Willem Dekker , Regional Director, Nycomed…

What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines,…

Interview with Lloyd Sansom, Emeritus Professor, Australia

Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee…

Interview with Fabian Dwyer, General Manager, IMS Health…

How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service…

Interview with Juliet Seifert , Executive Director, Australian…

Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international…

Interview with Brendan Shaw, Executive Director, Health Policy…

To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents…

Interview with Patrick Tete, CEO, SERVIER Laboratories…

Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main…

Interview with Dieter Torheiden, Managing Director, Solvay…

How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not…

Interview with Troy Guthrie, Managing Director, Stiefel…

What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although…

Interview with Hans-Dieter Hausner, Senior Bayer Representative,…

Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect?…

Interview with Suzanne Hill, Chair, Pharmaceutical Benefits…

To begin, would you please give a brief introduction to the PBAC? The PBAC is a statutory committee of government first developed in Australia in the…

Tagged with